Published in: Leukemia Research & Development

Targeted Treatment can Reduce Relapse in Children With Acute Myeloid Leukemia

Author DD4D

Published on: February 11, 2014

In pediatric patients with acute myeloid leukemia (AML), the addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival.

Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease.

The study (abstract #355) evaluated a total of 1,022 children averaging 10 years old at trial sites nationwide, led by Alan Gamis, MD, MPH, Associate Division Director, Section of Oncology at Children’s Mercy Hospital in Kansas City. It will be highlighted in an oral presentation Monday, Dec. 9, at the American Society of Hematology annual meeting in New Orleans.

[button size=’medium’ text=’Read More’ icon=” icon_size=” icon_color=” link=’http://www.medindia.net/news/targeted-treatment-can-reduce-relapse-in-children-with-acute-myeloid-leukemia-128962-1.htm#ixzz2t22ZTCh7′ target=’_blank’ color=” background_color=’#78c145′ border_color=” font_style=’normal’ font_weight=’500′ text_align=’center’]